5-HT6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer's Disease

Neurotherapeutics

Volumn 5, Issue 3, 2008, Pages 458-469

  Upton, Neil ^a   Chuang, Tsu Tshen ^a   Hunter, Ann J ^a   Virley, David J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT6 receptor antagonists; acetylcholine; Alzheimer's disease; behavioral symptoms; cognition; dopamine; glutamate; learning; memory; neural cell adhesion molecule; norepinephrine; SB 742457; synaptic plasticity

Indexed keywords

4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; AMFEBUTAMONE; DESIPRAMINE; DIZOCILPINE; PRX 07034; RECEPTOR SUBTYPE; RO 4368554; SAM 531; SB 399885; SB 742457; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SGS 518; SUVEN; SUVN 502; SYN 114; WAY 181187; WAY 466; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LEARNING; MEMORY; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; ANIMAL; COGNITIVE DEFECT; PHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 46749118971     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.05.008     Document Type: Article

References (99)

1. Brookmeyer R., Johnson E., Zeigler-Graham K., and Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimer's Dement 3 (2007) 186-191
2. Terry Jr. A.V., and Buccafusco J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306 (2003) 821-827
3. Courtney C., Farrell D., Gray R., et al., AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363 (2004) 2105-2115
4. Ramirez M.J., Aisa B., Garcia-Alloza M., Gil-Bea F.J., and Marcos B. Involvement of the serotonergic system in cognitive and behavioral symptoms of Alzheimer's disease. Curr Psychiatry Rev 1 (2005) 337-343
5. 6 receptor antagonist SB-742457 as a novel cognitive enhancing agent for Alzheimer's disease. Alzheimers Dement 2 (2006) S631-S632 (abstract)
6. Monsma Jr. F.J., Shen Y., Ward R.P., Hamblin M.W., and Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43 (1993) 320-327
7. 6) receptor: molecular cloning, localization, and stimulation of cAMP accumulation. Biochem Biophys Res Commun 193 (1993) 268-276
8. 125I]SB-258585. Brain Res 934 (2002) 49-57
9. 6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 23 (1996) 164-173
10. 6 receptors. Neuropsychopharmacology 21 Suppl 2 (1999) 68S-76S
11. 6 receptors. Curr Drug Targets CNS Neurol Disord 3 (2004) 59-79
12. Hirst W.D., Abrahamsen B., Blaney F.E., et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 64 (2003) 1295-1308
13. 6 serotonin receptor. J Neurochem 66 (1996) 47-56
14. 6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 108 (2005) 320-333
15. Roth B.L., Craigo S.C., Choudray M.S., et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268 (1994) 1403-1410
16. 6 receptors. Br J Pharmacol 124 (1998) 556-562
17. 6 receptor antagonist. J Med Chem 42 (1999) 202-205
18. 6 receptor antagonist. Br J Pharmacol 130 (2000) 1606-1612
19. 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 553 (2006) 109-119
20. 6 receptor antagonist. Soc Neurosci Abstr 884 (2002) 5 (abstract)
21. 6 receptor antagonist Ro4368554 in rat models for cognition and sensorimotor gating. Eur Neuropsychopharmacol 17 (2007) 277-288
22. 6 receptor agonist. Fundam Clin Pharmacol 18 Suppl 1 (2004) 135-151 SAT-P 7.5 (abstract)
23. 6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 33 (2008) 1323-1335
24. 6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology (Berl) 196 (2008) 93-104
25. 6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmacol Exp Ther 274 (1995) 173-180
26. 6 receptor antagonist, Ro 04-6790, in rats. Br J Pharmacol 126 (1999) 1537-1542
27. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66 (1999) 137-147
28. Perry E., Walker M., Grace J., and Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci 22 (1999) 273-280
29. 6 antisense oligonucleotide i.c.v. affects rat performance in the water maze and feeding. J Psychopharmacol 11 3 Suppl (1997) A64 (abstract)
30. 6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 41 (2001) 210-219
31. 6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berl) 158 (2001) 114-119
32. 6 receptor ligands and their biological functions. Curr Top Med Chem 2 (2002) 643-654
33. 6) receptor antagonists in rodent models of learning. J Pharmacol Exp Ther 307 (2003) 682-691
34. Bussey T.J., Muir J.L., and Aggleton J.P. Functionally dissociating aspects of event memory: the effects of combined perirhinal and postrhinal cortex lesions on object and place memory in the rat. J Neurosci 19 (1999) 495-502
35. 6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation: an effect sensitive to NMDA receptor antagonism. Neuropharmacology 47 (2004) 195-204
36. 6 receptor antagonist SB-271046 in behavioral models of cognition. Soc Neurosci Abstr (2004) 776.19 (abstract)
37. 6 receptor antagonist, Ro 04-6790. Psychopharmacology (Berl) 170 (2003) 358-367
38. 6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology 30 (2005) 2169-2179
39. Nirogi R.V., Vishwakarma S.L., Abraham R., Jayarajan P., Goyal R.K., and Shirsath V.S. SUVN-507 reverses scopolamine induced amnesia in Morris water maze and novel object recognition task. Soc Neurosci Abstr (2006) 162.12 (abstract)
40. 6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 29 (2004) 93-100
41. 6 receptor antagonist Ro4368554 in rats. Soc Neurosci Abstr (2002) 290.2 (abstract)
42. 6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol Biochem Behav 5;81:673-682.
43. 6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology (Berl) 181 (2005) 253-259
44. 6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 52 (2007) 1274-1283
45. Nikiforuk A., Wesołowska A., and Popik P. Effect of combined administration of the selective serotonin 6 receptor antagonist SB-399885 and antidepressants in the forced swim test in rats. Soc Neurosci Abstr (2007) 709.7 (abstract)
46. 6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behav Pharmacol 18 (2007) 439-446
47. 6 receptor antagonists on food-intake and body weight gain. Soc Neurosci Abstr (2005) 533.7 (abstract)
48. 6 ligand, E-6837, in a rat model of dietary-induced obesity. Soc Neurosci Abstr (2006) 62.2 (abstract)
49. 6 receptor antagonist in animal models for feeding and body weight regulation. Soc Neurosci Abstr (2007) 629.11 (abstract)
50. 6 receptor antagonist. J Med Chem 46 (2003) 1273-1276
51. Zhang M.Y., Hughes Z.A., Kerns E.H., Lin Q., and Beyer C.E. Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples. J Pharm Biomed Anal 44 (2007) 586-593
52. 6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br J Pharmacol 130 (2000) 23-26
53. 6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25 (2001) 662-668
54. Francis P.T., Sims N.R., Procter A.W., and Bowen D.M. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem 60 (1993) 1589-1604
55. Palmer A.M. Neurochemical studies of Alzheimer's disease. Neurodegeneration 5 (1996) 381-391
56. 6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 51 (2004) 158-164
57. Kolb B. Functions of the frontal cortex of the rat: a comparative review. Brain Res 320 (1984) 65-98
58. Passetti F., Chudasama Y., and Robbins T.W. The frontal cortex of the rat and visual attentional performance: dissociable functions of distinct medial prefrontal subregions. Cereb Cortex 12 (2002) 1254-1268
59. 6 receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat. J Neural Transm 110 (2003) 577-590
60. 6 receptor-mediated acetylcholine release. Eur J Neurosci 24 (2006) 1299-1306
61. 6 receptor-like material in the rat central nervous system. Brain Res 746 (1997) 207-219
62. Persohn E., and Schachner M. Immunoelectron microscopic localization of the neural cell adhesion molecules L1 and N-CAM during postnatal development of the mouse cerebellum. J Cell Biol 105 (1987) 569-576
63. Schuster T., Krug M., Stalder M., Hackel N., Gerardy-Schahn R., and Schachner M. Immunoelectron microscopic localization of the neural recognition molecules L1, NCAM, and its isoform NCAM180, the NCAM-associated polysialic acid, beta1 integrin and the extracellular matrix molecule tenascin-R in synapses of the adult rat hippocampus. J Neurobiol 49 (2001) 142-158
64. Doyle E., Nolan P.M., Bell R., and Regan C.M. Intraventricular infusions of anti-neural cell adhesion molecules in a discrete posttraining period impair consolidation of a passive avoidance response in the rat. J Neurochem 59 (1992) 1570-1573
65. Scholey A.B., Rose S.P., Zamani M.R., Bock E., and Schachner M. A role for the neural cell adhesion molecule in a late, consolidating phase of glycoprotein synthesis six hours following passive avoidance training of the young chick. Neuroscience 55 (1993) 499-509
66. Lüthl A., Laurent J.P., Figurov A., Muller D., and Schachner M. Hippocampal long-term potentiation and neural cell adhesion molecules L1 and NCAM. Nature 372 (1994) 777-779
67. Sadoul R., Hirn M., Deagostini-Bazin H., Rougon G., and Goridis C. Adult and embryonic mouse neural cell adhesion molecules have different binding properties. Nature 304 (1983) 347-349
68. Moran N., and Bock E. Characterization of the kinetics of neural cell adhesion molecule homophilic binding. FEBS Lett 242 (1988) 121-124
69. Muller D., Wang C., Skibo G., et al. PSA-NCAM is required for activity-induced synaptic plasticity. Neuron 7 (1996) 413-422
70. Becker C.G., Artola A., Gerardy-Schahn R., Becker T., Welzl H., and Schachner M. The polysialic acid modification of the neural cell adhesion molecule is involved in spatial learning and hippocampal long-term potentiation. J Neurosci Res 45 (1996) 143-152
71. Venero C., Herrero A.I., Touyarot K., et al. Hippocampal up-regulation of NCAM expression and polysialylation plays a key role on spatial memory. Eur J Neurosci 23 (2006) 1585-1595
72. Diyatev A., Dityateva G., Sytnyk V., et al. Polysialylated neural cell adhesion molecule promotes remodeling and formation of hippocampal synapses. J Neurosci 24 (2004) 9372-9382
73. Markram K., Gerardy-Schahn R., and Sandi C. Selective learning and memory impairments in mice deficient for polysialylated NCAM in adulthood. Neuroscience 144 (2007) 788-796
74. Seki T., and Arai Y. Highly polysialylated neural cell adhesion molecule (NCAM-H) is expressed by newly generated granule cells in the dentate gyrus of the adult rat. J Neurosci 13 (1993) 2351-2358
75. Seki T., and Arai Y. Different polysialic acid-neural cell adhesion molecule expression patterns in distinct types of mossy fiber boutons in the adult hippocampus. J Comp Neurol 410 (1999) 115-125
76. Ní Dhúill C.M., Fox G.B., Pittock S.J., O'Connell A.W., Murphy K.J., and Regan C.M. Polysialylated neural cell adhesion molecule expression in the dentate gyrus of the human hippocampal formation from infancy to old age. J Neurosci Res 55 (1999) 99-106
77. Ge S., Yang C.H., Hsu K.S., Ming G.L., and Song H. A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain. Neuron 54 (2007) 559-566
78. Zhao C., Teng E.M., Summers Jr. R.G., Ming G.L., and Gage F.H. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci 26 (2006) 3-11
79. Kee N., Teixeira C.M., Wang A.H., and Frankland P.W. Preferential incorporation of adult-generated granule cells into spatial memory networks in the dentate gyrus. Nat Neurosci 10 (2007) 355-362
80. Kitabatake Y., Sailor K.A., Ming G.L., and Song H. Adult neurogenesis and hippocampal memory function: new cells, more plasticity, new memories?. Neurosurg Clin N Am 18 (2007) 105-113
81. Senkov O., Sun M., Weinhold B., Gerardy-Schahn R., Schachner M., and Dityatev A. Polysialylated neural cell adhesion molecule is involved in induction of long-term potentiation and memory acquisition and consolidation in a fear-conditioning paradigm. J Neurosci 26 (2006) 10888-10898
82. Lopez-Fernandez M.A., Montaron M.F., Varea E., et al. Upregulation of polysialylated neural cell adhesion molecule in the dorsal hippocampus after contextual fear conditioning is involved in long-term memory formation. J Neurosci 27 (2007) 4552-4561
83. Johnson C.N., Roland A., and Upton N. New symptomatic strategies in Alzheimer's disease. Drug Discov Today Ther Strateg 1 (2004) 13-20
84. 6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology 54 (2008) 1166-1174
85. 6 receptor through an interaction with Fyn. J Biol Chem 282 (2007) 5496-5505
86. 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95 (1998) 6448-6453
87. Chin J., Palop J.J., Puoliväli J., et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25 (2005) 9694-9703
88. Lee G., Thangavel R., Sharma V.M., et al. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci 24 (2004) 2304-2312
89. Dunah A.W., Sirianni A.C., Fienberg A.A., Bastia E., Schwarzschild M.A., and Standaert D.G. Dopamine D1-dependent trafficking of striatal N-methyl-d-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol 65 (2004) 121-129
90. Grant S.G., O'Dell T.J., Karl K.A., Stein P.L., Soriano P., and Kandel E.R. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science 258 (1992) 1903-1910
91. Miyakawa T., Yagi T., Watanabe S., and Niki H. Increased fearfulness of Fyn tyrosine kinase deficient mice. Mol Brain Res 27 (1994) 179-182
92. Danysz W., and Parsons C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 18 Suppl 1 (2003) S23-S32
93. Birks J., and Harvey R.J. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) CD001190
94. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil. JAMA 291 (2004) 317-324
95. 1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology 39 (2000) 547-552
96. Schechter L.E., Smith D.L., Rosenzweig-Lipson S., et al. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 314 (2005) 1274-1289
97. Deisseroth K., Singla S., Toda H., Monje M., Palmer T.D., and Malenka R.C. Excitation-neurogenesis coupling in adult neural stem/progenitor cells. Neuron 42 (2004) 535-552
98. Murphy K.J., O'Connell A.W., and Regan C.M. Repetitive and transient increases in hippocampal neural cell adhesion molecule polysialylation state following multitrial spatial training. J Neurochem 67 (1996) 1268-1274
99. Fox G.B., O'Connell A.W., Murphy K.J., and Regan C.M. Memory consolidation induces a transient and time-dependent increase in the frequency of neural cell adhesion molecule polysialylated cells in the adult rat hippocampus. J Neurochem 65 (1995) 2796-2799